• Users Online: 578
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2021  |  Volume : 18  |  Issue : 3  |  Page : 196-199

Multiple sclerosis in 2020


1 Department of Neurology, Sir Ganga Ram Hospital, New Delhi, India
2 Department of Neurology, G B Pant Hospital, New Delhi, India

Correspondence Address:
Anshu Rohatgi
Senior Consultant Neurologist, Sir Ganga Ram Hospital, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/am.am_90_21

Rights and Permissions

Recent developments in the management of multiple sclerosis (MS) are ushering in a new era in MS treatment. The novel therapeutic disease-modifying agents that have been recently approved for the treatment of MS are B-cell therapies and various sphingosine-1-phosphate inhibitors. The Bruton's tyrosine kinase inhibitor therapies provide a novel therapeutic approach in the treatment of MS. Numerous studies have demonstrated a high degree of efficacy with autologous hematopoietic stem cells. There are upcoming trials focusing on remyelination strategies in MS. In this yearly review, we will focus on all these latest developments which are leading to a promising change in the diagnosis, treatment, and prognosis of this disease.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed216    
    Printed8    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal